Program 2: DECIPHER
DECIPHER: unDErstanding resistance of tumor eCosystems to develop and evaluate Innovative Promising tHERapies
Program coordinators:
The integrated research program DECIPHER is dedicated to understanding the disease by studying the relationships between cancer cells and the tumor microenvironment (the cellular environment in which the tumor develops), which plays a critical role in treatment resistance, particularly in multiple myeloma and breast cancer. The ultimate goal is to identify new molecular mechanisms and vulnerabilities that can be targeted by small molecules or other interventions such as targeted internal radiotherapy (TIR) based on alpha emitters, which is very promising. The objectives of this program are:
- Provide a multi-scale understanding, from single cell to whole body, and multiparametric (omics, imaging, functional tests) understanding of the resistance of tumor ecosystems.
- Propose a targeted therapeutic intervention strategy based on our understanding of the microenvironment landscape and knowledge of intrinsic tumor resistance (antibody-drug conjugates, antibodies targeting or stimulating the immune system, combined with (radio)pharmacological compounds).
- Develop new targeted tools for novel theranostic/therapeutic approaches, considering autologous or adoptive immune cells.
The DECIPHER program is organized into 4 research axes:
- WP5 : Vulnerabilities of resistances in the myeloma ecosystem.
Leads: Catherine Pellat, David Chiron - WP6: Features and vulnerabilities of residual/resistant BC ecotypes.
Leads: Philippe Juin, François Guillonneau - WP7: TAT to target resistance in BC : radioimmunobiological effects of new radio-pharmaceuticals.
Leads: François Guérard, Mathilde Allard - WP8: Dynamics imaging of innovative therapies (CAR T, bispecific antibodies) and immune cells
Leads: Clément Bailly, Michel Chérel